Geeta Devgan

3.9k total citations · 1 hit paper
25 papers, 3.3k citations indexed

About

Geeta Devgan is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Geeta Devgan has authored 25 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Geeta Devgan's work include Bladder and Urothelial Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Urinary and Genital Oncology Studies (5 papers). Geeta Devgan is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Urinary and Genital Oncology Studies (5 papers). Geeta Devgan collaborates with scholars based in United States, Japan and Poland. Geeta Devgan's co-authors include Jacqueline Bromberg, James Darnell, Richard G. Pestell, Chris Albanese, Yanxiang Zhao, Yuhong Shen, M Snyder, Keren Paz, Janeen Azare and Marjan Berishaj and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Geeta Devgan

23 papers receiving 3.3k citations

Hit Papers

Stat3 as an Oncogene 1999 2026 2008 2017 1999 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Stat3 as an Oncogene
    1999 2.5k citations Jacqueline Bromberg, Geeta Devgan et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geeta Devgan United States 12 2.3k 1.6k 908 562 533 25 3.3k
Jiehui Deng United States 21 1.4k 0.6× 1.5k 0.9× 1.0k 1.1× 300 0.5× 601 1.1× 34 2.9k
Linda Mora United States 15 1.6k 0.7× 1.3k 0.8× 467 0.5× 498 0.9× 473 0.9× 29 2.6k
Marc M. Oshiro United States 20 1.6k 0.7× 2.2k 1.3× 611 0.7× 568 1.0× 552 1.0× 24 3.4k
Ralf Buettner United States 24 2.9k 1.3× 2.9k 1.8× 1.1k 1.2× 834 1.5× 1.1k 2.0× 63 5.6k
Guilian Niu United States 16 3.6k 1.6× 2.6k 1.6× 2.0k 2.2× 878 1.6× 1.1k 2.1× 19 5.7k
Tammy Bowman United States 16 3.9k 1.7× 2.9k 1.8× 1.1k 1.3× 1.1k 1.9× 894 1.7× 19 5.4k
Manfred Jücker Germany 30 904 0.4× 2.0k 1.2× 518 0.6× 451 0.8× 553 1.0× 104 3.2k
Chao‐Lan Yu United States 18 1.5k 0.7× 1.5k 0.9× 717 0.8× 374 0.7× 352 0.7× 40 2.6k
Heehyoung Lee United States 24 3.0k 1.3× 3.0k 1.8× 2.1k 2.3× 717 1.3× 1.6k 3.1× 26 6.2k
Yohko Hikiba Japan 28 776 0.3× 1.3k 0.8× 405 0.4× 319 0.6× 542 1.0× 45 2.5k

Countries citing papers authored by Geeta Devgan

Since Specialization
Citations

This map shows the geographic impact of Geeta Devgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geeta Devgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geeta Devgan more than expected).

Fields of papers citing papers by Geeta Devgan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geeta Devgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geeta Devgan. The network helps show where Geeta Devgan may publish in the future.

Co-authorship network of co-authors of Geeta Devgan

This figure shows the co-authorship network connecting the top 25 collaborators of Geeta Devgan. A scholar is included among the top collaborators of Geeta Devgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geeta Devgan. Geeta Devgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McKay, Rana R., Alicia K. Morgans, Neal D. Shore, et al.. (2024). First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States. Cancer Treatment Reviews. 126. 102726–102726. 9 indexed citations
2.
3.
Swami, Umang, Pedro C. Barata, Allison Thompson, et al.. (2024). MP68-16 REAL WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR NOVEL HORMONAL THERAPY AND TAXANE USE. The Journal of Urology. 211(5S). 2 indexed citations
4.
5.
Wood, Laura S., et al.. (2022). Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses. Journal of Infusion Nursing. 45(3). 142–153. 4 indexed citations
6.
Grivas, Petros, Pedro C. Barata, Helen Moon, et al.. (2022). PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.. Journal of Clinical Oncology. 40(6_suppl). TPS578–TPS578. 2 indexed citations
7.
Gupta, Shilpa, et al.. (2022). Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study.. Journal of Clinical Oncology. 40(6_suppl). 456–456. 4 indexed citations
8.
Grivas, Petros, Neeraj Agarwal, Sumanta K. Pal, et al.. (2021). Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treatment Reviews. 97. 102187–102187. 35 indexed citations
9.
10.
Chioda, Marc, et al.. (2020). Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners. Advances in Therapy. 37(6). 3019–3030. 36 indexed citations
11.
Corral, J., Tony Mok, Kazuhiko Nakagawa, et al.. (2019). Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer. Future Oncology. 15(24). 2795–2805. 30 indexed citations
12.
Pujade-Lauraine, Éric, Keiichi Fujiwara, Samuel S. Dychter, Geeta Devgan, & Bradley J. Monk. (2018). Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design. Future Oncology. 14(21). 2103–2113. 58 indexed citations
13.
Mok, Tony, Kazuhiko Nakagawa, Rafael Rosell, et al.. (2018). MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC. Journal of Thoracic Oncology. 13(10). S454–S454. 5 indexed citations
14.
Talarek, Nicolas, Elisabetta Cameroni, Malika Jaquenoud, et al.. (2010). Initiation of the TORC1-Regulated G0 Program Requires Igo1/2, which License Specific mRNAs to Evade Degradation via the 5′-3′ mRNA Decay Pathway. Molecular Cell. 38(3). 345–355. 94 indexed citations
15.
Devgan, Geeta, Jason Ptacek, Mike Schutkowski, et al.. (2005). Substrate specificity analysis of protein kinase complex Dbf2-Mob1 by peptide library and proteome array screening. BMC Biochemistry. 6(1). 22–22. 81 indexed citations
16.
Smith, Michael G., Ghil Jona, Jason Ptacek, et al.. (2004). Global analysis of protein function using protein microarrays. Mechanisms of Ageing and Development. 126(1). 171–175. 28 indexed citations
17.
Zhu, Heng, Bilgin Metin, Jason Ptacek, et al.. (2003). Workshop I – Global Analysis of Protein Activities Using Protein Chips. Biophysical Journal. 84(5). 3488–3488. 1 indexed citations
18.
Messmer, Davorka, Jacqueline Bromberg, Geeta Devgan, et al.. (2002). Short Communications: Human Immunodeficiency Virus Type 1 Nef Mediates Activation of STAT3 in Immature Dendritic Cells. AIDS Research and Human Retroviruses. 18(14). 1043–1050. 21 indexed citations
19.
Bromberg, Jacqueline, Geeta Devgan, Yanxiang Zhao, et al.. (1999). Stat3 as an Oncogene. Cell. 99(2). 238–239. 5 indexed citations
20.
Bromberg, Jacqueline, Geeta Devgan, Yanxiang Zhao, et al.. (1999). Stat3 as an Oncogene. Cell. 98(3). 295–303. 2453 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiehui Deng Breakdown of academic impact, for papers by Linda Mora Breakdown of academic impact, for papers by Marc M. Oshiro Breakdown of academic impact, for papers by Ralf Buettner Breakdown of academic impact, for papers by Guilian Niu Breakdown of academic impact, for papers by Tammy Bowman Breakdown of academic impact, for papers by Manfred Jücker Breakdown of academic impact, for papers by Chao‐Lan Yu Breakdown of academic impact, for papers by Heehyoung Lee Breakdown of academic impact, for papers by Yohko Hikiba
Rankless by CCL
2026